论文部分内容阅读
目的比较卡维地洛和美托洛尔治疗慢性心力衰竭患者的疗效和安全性。方法80例慢性心力衰竭患者以1∶1随机分为卡维地洛组(40例)和美托洛尔组(40例)测定治疗前后临床心功能分级,血压、心率、左心室功能及血糖、血脂水平及肾功能。结果两组治疗后心功能均改善,左心室射血分数增高,收缩末期容量降低(P<0.05)。治疗后,血糖、肌酐变化值卡维地洛组与美托洛尔组比较差异有统计学意义(P<0.05),而总胆固醇(TC)、低密度脂蛋白胆固醇(LDL-C)变化值卡维地洛组与美托洛尔组比较差异无统计学意义。结论卡维地洛治疗慢性心功能不全,患者安全,疗效与美托洛尔相似,但前者对糖代谢和肾功能可能有益。
Objective To compare the efficacy and safety of carvedilol and metoprolol in the treatment of patients with chronic heart failure. Methods Eighty patients with chronic heart failure were randomly divided into carvedilol group (40 cases) and metoprolol group (40 cases) at 1: 1. Before and after treatment, the levels of clinical cardiac function, blood pressure, heart rate, left ventricular function and blood glucose, Lipid levels and renal function. Results After treatment, heart function improved, left ventricular ejection fraction increased, and the end systolic volume decreased (P <0.05). After treatment, the changes of blood glucose and creatinine in carvedilol group and metoprolol group were significantly different (P <0.05), while the levels of total cholesterol (TC), low density lipoprotein cholesterol (LDL-C) There was no significant difference between carvedilol group and metoprolol group. Conclusions Carvedilol is a safe and effective treatment for chronic heart failure, which is similar to metoprolol, but the former may be beneficial to glucose metabolism and renal function.